Abstracts tagged "genetics and interferons"

Abstract Number: 2813 • 2017 ACR/ARHP Annual Meeting
Interferon-Induced APOL1 over-Expression Causes Autophagic Dysfunction and Mitochondrial Stress in Risk Variant-Carrying Endothelial Cells
Ashira Blazer¹, Sara Rasmussen², Androo Markham³, Shilpi Mehta-Lee⁴, Jill P. Buyon⁴ and Robert M. Clancy², ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Medicine, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: In SLE Apolipoprotein L1 (APOL1) risk variants (RV) associate with cardiovascular and end stage renal disease. APOL1 induction initially promotes cellular maintenance through autophagy;…
Abstract Number: 2798 • 2015 ACR/ARHP Annual Meeting
Increased Frequency of the PTPN22W* Variant in Primary Sjögren’s Syndrome-Association with Low Type I IFN Scores in Peripheral Blood
Nikolaos Vlachogiannis¹, Eliona Gkioka², Adrianos Nezos³ and Clio Mavragani⁴, ¹Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Physiology, Department of Experimental Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ³Physiology, Department of Experimental Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ⁴Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Protein tyrosine phosphatase non-receptor 22 (PTPN22) gene encodes a protein tyrosine phosphatase previously shown to inhibit antigen-receptor signaling in T cells and promoting type…
Abstract Number: 2772 • 2013 ACR/ARHP Annual Meeting
Identification Of a Sjögren’s Syndrome-Associated Variant That Influences OAS1 Isoform Switching
He Li^1,2, John A. Ice³, Jennifer A. Kelly³, Indra Adrianto¹, Stuart B. Glenn³, Kimberly S. Hefner⁴, Evan G. Vista⁵, Donald U. Stone⁶, Raj Gopalakrishnan⁷, Glen D. Houston⁸, David M. Lewis⁹, Michael Rohrer⁷, Pamela Hughes⁷, John B. Harley^10,11, Courtney G. Montgomery³, James Chodosh¹², James A. Lessard¹³, Juan-Manuel Anaya¹⁴, Barbara M. Segal¹⁵, Nelson L. Rhodus¹⁶, Lida Radfar², R. Hal Scofield¹⁷, Christopher J. Lessard^3,18 and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁵Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁶Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁸Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹¹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹³Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁴Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, ¹⁵Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a common, progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of the European population.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].